✦ LIBER ✦

Antibody therapy of non-Hodgkin's B-cell lymphoma

✍ Scribed by Paul Chinn; Gary Braslawsky; Christine White; Nabil Hanna

Publisher: Springer-Verlag
Year: 2003
Tongue: English
Weight: 342 KB
Volume: 52
Category: Article
ISSN: 0340-7004
DOI: 10.1007/s00262-002-0347-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Quality of life during maintenance thera

Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin’s lymphoma: results of a prospective randomized controlled trial

✍ Mathias Witzens-Harig; Monika Reiz; Christiane Heiß; Axel Benner; Manfred Hensel 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 139 KB

Monoclonal antibody (MoAb) therapy in no

Monoclonal antibody (MoAb) therapy in non-Hodgkin's lymphomas

✍ S.H. Lim; R.E. Marcus 📂 Article 📅 1992 🏛 Elsevier Science 🌐 English ⚖ 902 KB

Radioimmunotherapy of B-cell non-Hodgkin

Radioimmunotherapy of B-cell non-Hodgkin's lymphoma

✍ Ernst J. Postema; Otto C. Boerman; Wim J. Oyen; John M. Raemaekers; Frans H. Cor 📂 Article 📅 2001 🏛 Springer 🌐 English ⚖ 59 KB

Therapy of non-Hodgkin's lymphoma

✍ J. Coffey; D. C. Hodgson; M. K. Gospodarowicz 📂 Article 📅 2003 🏛 Springer 🌐 English ⚖ 160 KB

AGGRESSIVE NON-HODGKIN'S LYMPHOMA: T-CEL

AGGRESSIVE NON-HODGKIN'S LYMPHOMA: T-CELL VERSUS B-CELL

✍ RAYMOND LIANG; DAVID TODD; FAITH C. S. HO 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 364 KB 👁 2 views

This study aimed to define the clinical characteristics, treatment outcome and independent prognostic factors of 144 patients with T-and 357 B-cell non-Hodgkin's lymphomas. Entities with well-defined immunophenotype and clinical characteristics were excluded. Patients with T-cell tumours were younge

Interferon therapy of non-Hodgkin's lymp

Interferon therapy of non-Hodgkin's lymphoma

✍ Kenneth A. Foon; Mark S. Roth; Paul A. Bunn Jr 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 459 KB 👁 2 views

In 1981, the National Cancer Institute undertook Phase I1 trials of interferon alfa-2a in patients with non-Hodgkin's lymphoma (including cutaneous T-cell lymphoma [CTCL]) and chronic lymphocytic leukemia (CLL). A dose of 50 X lo6 U/m2, three times per week, was used initially, then adjusted downwar